NRAS
Summary: This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia. [provided by RefSeq, Jun 2011].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| NRAS proto-oncogene, GTPase | MIM:164790 | Ensembl:ENSG00000213281 | HGNC:HGNC:7989 | PA31768 | 1p13.2 |
Gene Categories:
CLINICALLY ACTIONABLEGO terms in NRAS
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | TAS | GO:0000165 | MAPK cascade |
| BP | IMP | GO:0001938 | positive regulation of endothelial cell proliferation |
| BP | TAS | GO:0002223 | stimulatory C-type lectin receptor signaling pathway |
| BP | TAS | GO:0007265 | Ras protein signal transduction |
| BP | TAS | GO:0043312 | neutrophil degranulation |
| CC | IEA | GO:0000139 | Golgi membrane |
| CC | IDA | GO:0005794 | Golgi apparatus |
| CC | TAS | GO:0005886 | plasma membrane |
| CC | HDA | GO:0016020 | membrane |
| CC | HDA | GO:0070062 | extracellular exosome |
| CC | TAS | GO:0070821 | tertiary granule membrane |
| MF | IEA | GO:0003924 | GTPase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005525 | GTP binding |
| MF | IDA | GO:0044877 | protein-containing complex binding |
Gene expression in normal tissue: NRAS
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in NRAS
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| wikipathways | WP2261 | Signaling Pathways in Glioblastoma |
| wikipathways | WP2290 | RalA downstream regulated genes |
| wikipathways | WP231 | TNF alpha Signaling Pathway |
| wikipathways | WP2586 | Aryl Hydrocarbon Receptor |
| wikipathways | WP2870 | Extracellular vesicle-mediated signaling in recipient cells |
| wikipathways | WP3303 | Rac1-Pak1-p38-MMP-2 pathway |
| wikipathways | WP35 | G Protein Signaling Pathways |
| wikipathways | WP3676 | BDNF-TrkB Signaling |
| wikipathways | WP382 | MAPK Signaling Pathway |
| wikipathways | WP3844 | PI3K-AKT-mTOR signaling pathway and therapeutic opportunities |
| wikipathways | WP3929 | Chemokine signaling pathway |
| wikipathways | WP3932 | Focal Adhesion-PI3K-Akt-mTOR-signaling pathway |
| wikipathways | WP4155 | Endometrial cancer |
| wikipathways | WP4172 | PI3K-Akt Signaling Pathway |
| wikipathways | WP4205 | MET in type 1 papillary renal cell carcinoma |
| wikipathways | WP422 | MAPK Cascade |
| wikipathways | WP4223 | Ras Signaling |
| wikipathways | WP51 | Regulation of Actin Cytoskeleton |
| wikipathways | WP710 | DNA Damage Response (only ATM dependent) |
| wikipathways | WP732 | Serotonin Receptor 2 and ELK-SRF-GATA4 signaling |
| smpdb | SMP00358 | Fc Epsilon Receptor I Signaling in Mast Cells |
| pid | cd8tcrdownstreampathway | Downstream signaling in naïve CD8+ T cells |
| pid | cd8tcrpathway | TCR signaling in naïve CD8+ T cells |
| pid | cmyb_pathway | C-MYB transcription factor network |
| pid | cxcr3pathway | CXCR3-mediated signaling events |
| pid | ephbfwdpathway | EPHB forward signaling |
| pid | er_nongenomic_pathway | Plasma membrane estrogen receptor signaling |
| pid | erbb1_downstream_pathway | ErbB1 downstream signaling |
| pid | erbb1_internalization_pathway | Internalization of ErbB1 |
| pid | erbb2erbb3pathway | ErbB2/ErbB3 signaling events |
| pid | gmcsf_pathway | GMCSF-mediated signaling events |
| pid | il2_1pathway | IL2-mediated signaling events |
| pid | mapktrkpathway | Trk receptor signaling mediated by the MAPK pathway |
| pid | mtor_4pathway | mTOR signaling pathway |
| pid | pdgfrbpathway | PDGFR-beta signaling pathway |
| pid | pi3kcipathway | Class I PI3K signaling events |
| pid | pi3kplctrkpathway | Trk receptor signaling mediated by PI3K and PLC-gamma |
| pid | ras_pathway | Regulation of Ras family activation |
| pid | shp2_pathway | SHP2 signaling |
| pid | tcr_pathway | TCR signaling in naïve CD4+ T cells |
| pid | tcrraspathway | Ras signaling in the CD4+ TCR pathway |
| pid | trkrpathway | Neurotrophic factor-mediated Trk receptor signaling |
| pharmgkb | PA154423660 | Bisphosphonate Pathway, Pharmacodynamics |
| pharmgkb | PA162356267 | EGFR Inhibitor Pathway, Pharmacodynamics |
| pharmgkb | PA165959425 | Pathway_PA165959425 |
| pharmgkb | PA165959584 | Sorafenib Pharmacodynamics |
| pharmgkb | PA165980050 | Vemurafenib Pathway, Pharmacodynamics |
| pharmgkb | PA165980050 | update your name in edit mode |
| pharmgkb | PA2032 | VEGF Signaling Pathway |
| kegg | hsa04010 | MAPK signaling pathway - Homo sapiens (human) |
| kegg | hsa04012 | ErbB signaling pathway - Homo sapiens (human) |
| kegg | hsa04014 | Ras signaling pathway - Homo sapiens (human) |
| kegg | hsa04015 | Rap1 signaling pathway - Homo sapiens (human) |
| kegg | hsa04062 | Chemokine signaling pathway - Homo sapiens (human) |
| kegg | hsa04068 | FoxO signaling pathway - Homo sapiens (human) |
| kegg | hsa04071 | Sphingolipid signaling pathway - Homo sapiens (human) |
| kegg | hsa04072 | Phospholipase D signaling pathway - Homo sapiens (human) |
| kegg | hsa04137 | Mitophagy - animal - Homo sapiens (human) |
| kegg | hsa04140 | Autophagy - animal - Homo sapiens (human) |
| kegg | hsa04150 | mTOR signaling pathway - Homo sapiens (human) |
| kegg | hsa04151 | PI3K-Akt signaling pathway - Homo sapiens (human) |
| kegg | hsa04210 | Apoptosis - Homo sapiens (human) |
| kegg | hsa04211 | Longevity regulating pathway - Homo sapiens (human) |
| kegg | hsa04213 | Longevity regulating pathway - multiple species - Homo sapiens (human) |
| kegg | hsa04218 | Cellular senescence - Homo sapiens (human) |
| kegg | hsa04360 | Axon guidance - Homo sapiens (human) |
| kegg | hsa04370 | VEGF signaling pathway - Homo sapiens (human) |
| kegg | hsa04371 | Apelin signaling pathway - Homo sapiens (human) |
| kegg | hsa04540 | Gap junction - Homo sapiens (human) |
| kegg | hsa04550 | Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human) |
| kegg | hsa04625 | C-type lectin receptor signaling pathway - Homo sapiens (human) |
| kegg | hsa04650 | Natural killer cell mediated cytotoxicity - Homo sapiens (human) |
| kegg | hsa04660 | T cell receptor signaling pathway - Homo sapiens (human) |
| kegg | hsa04662 | B cell receptor signaling pathway - Homo sapiens (human) |
| kegg | hsa04664 | Fc epsilon RI signaling pathway - Homo sapiens (human) |
| kegg | hsa04714 | Thermogenesis - Homo sapiens (human) |
| kegg | hsa04720 | Long-term potentiation - Homo sapiens (human) |
| kegg | hsa04722 | Neurotrophin signaling pathway - Homo sapiens (human) |
| kegg | hsa04725 | Cholinergic synapse - Homo sapiens (human) |
| kegg | hsa04726 | Serotonergic synapse - Homo sapiens (human) |
| kegg | hsa04730 | Long-term depression - Homo sapiens (human) |
| kegg | hsa04810 | Regulation of actin cytoskeleton - Homo sapiens (human) |
| kegg | hsa04910 | Insulin signaling pathway - Homo sapiens (human) |
| kegg | hsa04912 | GnRH signaling pathway - Homo sapiens (human) |
| kegg | hsa04915 | Estrogen signaling pathway - Homo sapiens (human) |
| kegg | hsa04916 | Melanogenesis - Homo sapiens (human) |
| kegg | hsa04917 | Prolactin signaling pathway - Homo sapiens (human) |
| kegg | hsa04919 | Thyroid hormone signaling pathway - Homo sapiens (human) |
| kegg | hsa04921 | Oxytocin signaling pathway - Homo sapiens (human) |
| kegg | hsa04926 | Relaxin signaling pathway - Homo sapiens (human) |
| kegg | hsa04933 | AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human) |
| kegg | hsa05034 | Alcoholism - Homo sapiens (human) |
| kegg | hsa05160 | Hepatitis C - Homo sapiens (human) |
| kegg | hsa05161 | Hepatitis B - Homo sapiens (human) |
| kegg | hsa05165 | Human papillomavirus infection - Homo sapiens (human) |
| kegg | hsa05166 | HTLV-I infection - Homo sapiens (human) |
| kegg | hsa05167 | Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05203 | Viral carcinogenesis - Homo sapiens (human) |
| kegg | hsa05205 | Proteoglycans in cancer - Homo sapiens (human) |
| kegg | hsa05206 | MicroRNAs in cancer - Homo sapiens (human) |
| kegg | hsa05210 | Colorectal cancer - Homo sapiens (human) |
| kegg | hsa05211 | Renal cell carcinoma - Homo sapiens (human) |
| kegg | hsa05213 | Endometrial cancer - Homo sapiens (human) |
| kegg | hsa05214 | Glioma - Homo sapiens (human) |
| kegg | hsa05215 | Prostate cancer - Homo sapiens (human) |
| kegg | hsa05216 | Thyroid cancer - Homo sapiens (human) |
| kegg | hsa05218 | Melanoma - Homo sapiens (human) |
| kegg | hsa05219 | Bladder cancer - Homo sapiens (human) |
| kegg | hsa05220 | Chronic myeloid leukemia - Homo sapiens (human) |
| kegg | hsa05221 | Acute myeloid leukemia - Homo sapiens (human) |
| kegg | hsa05223 | Non-small cell lung cancer - Homo sapiens (human) |
| kegg | hsa05224 | Breast cancer - Homo sapiens (human) |
| kegg | hsa05225 | Hepatocellular carcinoma - Homo sapiens (human) |
| kegg | hsa05226 | Gastric cancer - Homo sapiens (human) |
| kegg | hsa05230 | Central carbon metabolism in cancer - Homo sapiens (human) |
| kegg | hsa05231 | Choline metabolism in cancer - Homo sapiens (human) |
| humancyc | PWY66-14 | MAP kinase cascade |
| reactome | R-HSA-109582 | Hemostasis |
| reactome | R-HSA-112399 | IRS-mediated signalling |
| reactome | R-HSA-112412 | SOS-mediated signalling |
| reactome | R-HSA-1168372 | Downstream signaling events of B Cell Receptor (BCR) |
| reactome | R-HSA-1169092 | Activation of RAS in B cells |
| reactome | R-HSA-1226099 | Signaling by FGFR in disease |
| reactome | R-HSA-1227986 | Signaling by ERBB2 |
| reactome | R-HSA-1227986 | Signaling by ERBB2 |
| reactome | R-HSA-1236382 | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants |
| reactome | R-HSA-1236394 | Signaling by ERBB4 |
| reactome | R-HSA-1250196 | SHC1 events in ERBB2 signaling |
| reactome | R-HSA-1250347 | SHC1 events in ERBB4 signaling |
| reactome | R-HSA-1266738 | Developmental Biology |
| reactome | R-HSA-1280218 | Adaptive Immune System |
| reactome | R-HSA-1433557 | Signaling by SCF-KIT |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-1643713 | Signaling by EGFR in Cancer |
| reactome | R-HSA-166520 | Signaling by NTRKs |
| reactome | R-HSA-166520 | Signaling by NTRKs |
| reactome | R-HSA-167044 | Signalling to RAS |
| reactome | R-HSA-167044 | Signalling to RAS |
| reactome | R-HSA-168249 | Innate Immune System |
| reactome | R-HSA-168256 | Immune System |
| reactome | R-HSA-171007 | p38MAPK events |
| reactome | R-HSA-171007 | p38MAPK events |
| reactome | R-HSA-177929 | Signaling by EGFR |
| reactome | R-HSA-179812 | GRB2 events in EGFR signaling |
| reactome | R-HSA-180336 | SHC1 events in EGFR signaling |
| reactome | R-HSA-186763 | Downstream signal transduction |
| reactome | R-HSA-186797 | Signaling by PDGF |
| reactome | R-HSA-187037 | Signaling by NTRK1 (TRKA) |
| reactome | R-HSA-187037 | Signaling by NTRK1 (TRKA) |
| reactome | R-HSA-187687 | Signalling to ERKs |
| reactome | R-HSA-187687 | Signalling to ERKs |
| reactome | R-HSA-190236 | Signaling by FGFR |
| reactome | R-HSA-194138 | Signaling by VEGF |
| reactome | R-HSA-1963640 | GRB2 events in ERBB2 signaling |
| reactome | R-HSA-1963640 | GRB2 events in ERBB2 signaling |
| reactome | R-HSA-202733 | Cell surface interactions at the vascular wall |
| reactome | R-HSA-210993 | Tie2 Signaling |
| reactome | R-HSA-2172127 | DAP12 interactions |
| reactome | R-HSA-2179392 | EGFR Transactivation by Gastrin |
| reactome | R-HSA-2404192 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
| reactome | R-HSA-2424491 | DAP12 signaling |
| reactome | R-HSA-2428924 | IGF1R signaling cascade |
| reactome | R-HSA-2428928 | IRS-related events triggered by IGF1R |
| reactome | R-HSA-2428933 | SHC-related events triggered by IGF1R |
| reactome | R-HSA-2454202 | Fc epsilon receptor (FCERI) signaling |
| reactome | R-HSA-2871796 | FCERI mediated MAPK activation |
| reactome | R-HSA-372790 | Signaling by GPCR |
| reactome | R-HSA-375165 | NCAM signaling for neurite out-growth |
| reactome | R-HSA-388396 | GPCR downstream signalling |
| reactome | R-HSA-416476 | G alpha (q) signalling events |
| reactome | R-HSA-422475 | Axon guidance |
| reactome | R-HSA-4420097 | VEGFA-VEGFR2 Pathway |
| reactome | R-HSA-5218921 | VEGFR2 mediated cell proliferation |
| reactome | R-HSA-5621481 | C-type lectin receptors (CLRs) |
| reactome | R-HSA-5621575 | CD209 (DC-SIGN) signaling |
| reactome | R-HSA-5637810 | Constitutive Signaling by EGFRvIII |
| reactome | R-HSA-5637812 | Signaling by EGFRvIII in Cancer |
| reactome | R-HSA-5637815 | Signaling by Ligand-Responsive EGFR Variants in Cancer |
| reactome | R-HSA-5654687 | Downstream signaling of activated FGFR1 |
| reactome | R-HSA-5654688 | SHC-mediated cascade:FGFR1 |
| reactome | R-HSA-5654693 | FRS-mediated FGFR1 signaling |
| reactome | R-HSA-5654696 | Downstream signaling of activated FGFR2 |
| reactome | R-HSA-5654699 | SHC-mediated cascade:FGFR2 |
| reactome | R-HSA-5654700 | FRS-mediated FGFR2 signaling |
| reactome | R-HSA-5654704 | SHC-mediated cascade:FGFR3 |
| reactome | R-HSA-5654706 | FRS-mediated FGFR3 signaling |
| reactome | R-HSA-5654708 | Downstream signaling of activated FGFR3 |
| reactome | R-HSA-5654712 | FRS-mediated FGFR4 signaling |
| reactome | R-HSA-5654716 | Downstream signaling of activated FGFR4 |
| reactome | R-HSA-5654719 | SHC-mediated cascade:FGFR4 |
| reactome | R-HSA-5654736 | Signaling by FGFR1 |
| reactome | R-HSA-5654738 | Signaling by FGFR2 |
| reactome | R-HSA-5654741 | Signaling by FGFR3 |
| reactome | R-HSA-5654743 | Signaling by FGFR4 |
| reactome | R-HSA-5655253 | Signaling by FGFR2 in disease |
| reactome | R-HSA-5655291 | Signaling by FGFR4 in disease |
| reactome | R-HSA-5655302 | Signaling by FGFR1 in disease |
| reactome | R-HSA-5655332 | Signaling by FGFR3 in disease |
| reactome | R-HSA-5658442 | Regulation of RAS by GAPs |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5673000 | RAF activation |
| reactome | R-HSA-5673001 | RAF/MAP kinase cascade |
| reactome | R-HSA-5674135 | MAP2K and MAPK activation |
| reactome | R-HSA-5675221 | Negative regulation of MAPK pathway |
| reactome | R-HSA-5683057 | MAPK family signaling cascades |
| reactome | R-HSA-5684996 | MAPK1/MAPK3 signaling |
| reactome | R-HSA-6798695 | Neutrophil degranulation |
| reactome | R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants |
| reactome | R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants |
| reactome | R-HSA-6802949 | Signaling by RAS mutants |
| reactome | R-HSA-6802952 | Signaling by BRAF and RAF fusions |
| reactome | R-HSA-6802953 | RAS signaling downstream of NF1 loss-of-function variants |
| reactome | R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF |
| reactome | R-HSA-6802957 | Oncogenic MAPK signaling |
| reactome | R-HSA-6806834 | Signaling by MET |
| reactome | R-HSA-74751 | Insulin receptor signalling cascade |
| reactome | R-HSA-74752 | Signaling by Insulin receptor |
| reactome | R-HSA-881907 | Gastrin-CREB signalling pathway via PKC and MAPK |
| reactome | R-HSA-8848021 | Signaling by PTK6 |
| reactome | R-HSA-8849471 | PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases |
| reactome | R-HSA-8851805 | MET activates RAS signaling |
| reactome | R-HSA-8853334 | Signaling by FGFR3 fusions in cancer |
| reactome | R-HSA-8853338 | Signaling by FGFR3 point mutants in cancer |
| reactome | R-HSA-9006115 | Signaling by NTRK2 (TRKB) |
| reactome | R-HSA-9006927 | Signaling by Non-Receptor Tyrosine Kinases |
| reactome | R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases |
| reactome | R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases |
| reactome | R-HSA-9026519 | Activated NTRK2 signals through RAS |
| reactome | R-HSA-9028731 | Activated NTRK2 signals through FRS2 and FRS3 |
| reactome | R-HSA-9034015 | Signaling by NTRK3 (TRKC) |
| reactome | R-HSA-9034864 | Activated NTRK3 signals through RAS |
| reactome | R-HSA-983705 | Signaling by the B Cell Receptor (BCR) |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD463 | ZSTK 474 | 1 |
| iGMDRD792 | Cetuximab | 12 |
| iGMDRD148 | Pifithrin-mu | 2 |
| iGMDRD32 | Metformin | 1 |
| iGMDRD604 | 4449-51-8 | 1 |
| iGMDRD689 | EX-8678 | 1 |
| iGMDRD57 | Chloropentafluorobenzene | 7 |
| iGMDRD536 | PLX-4720 | 5 |
| iGMDRD435 | BI-2536 | 5 |
| iGMDRD785 | XMD15-27 | 1 |
| iGMDRD386 | TAK-715 | 1 |
| iGMDRD514 | ERK inhibitor | 4 |
| iGMDRD310 | Everolimus | 1 |
| iGMDRD481 | Dactolisib | 3 |
| iGMDRD333 | MEK Inhibitor | 28 |
| iGMDRD551 | Ponatinib | 2 |
| iGMDRD967 | Panitumumab | 10 |
| iGMDRD3 | PD-173074 | 1 |
| iGMDRD886 | Compound 1541A | 2 |
| iGMDRD191 | FMK | 2 |
| iGMDRD246 | NPC26 | 1 |
| iGMDRD556 | Quizartinib | 1 |
| iGMDRD695 | FR-180204 | 2 |
| iGMDRD282 | GNF-2 | 1 |
| iGMDRD361 | 5Z-7-Oxozeaenol | 1 |
| iGMDRD638 | Ribociclib | 3 |
| iGMDRD446 | LY 2183240 | 1 |
| iGMDRD66 | Doxorubicin | 1 |
| iGMDRD280 | CYTOCHALASIN B | 5 |
| iGMDRD134 | Sorafenib | 4 |
| iGMDRD261 | OSI-027 | 2 |
| iGMDRD335 | MEK Inhibitor +/- PI3K pathway inhibitor | 4 |
| iGMDRD309 | 17AAG | 2 |
| iGMDRD692 | SB590885 | 1 |
| iGMDRD432 | AT-7519 | 1 |
| iGMDRD291 | AC1NS4S0 | 1 |
| iGMDRD451 | Serdemetan | 1 |
| iGMDRD392 | Masitinib | 1 |
| iGMDRD436 | GSK429286A | 1 |
| iGMDRD584 | VER 155008 | 5 |
| iGMDRD276 | AS 605240 | 1 |
| iGMDRD581 | Omipalisib | 1 |
| iGMDRD775 | NCGC00346967-01 | 2 |
| iGMDRD406 | Binimetinib | 10 |
| iGMDRD1018 | TL-1-85 | 2 |
| iGMDRD352 | PD-0325901 | 1 |
| iGMDRD997 | Radioiodine Uptake Therapy | 2 |
| iGMDRD123 | Isoevodiamine | 1 |
| iGMDRD39 | Pyrimethamine | 1 |
| iGMDRD672 | Alectinib | 1 |
| iGMDRD103 | SN-38 | 1 |
| iGMDRD202 | Curcumin | 3 |
| iGMDRD158 | NSC141540 | 2 |
| iGMDRD293 | Bleomycin | 1 |
| iGMDRD455 | Idelalisib | 2 |
| iGMDRD311 | Dacinostat | 1 |
| iGMDRD662 | JQ-1 | 1 |
| iGMDRD264 | Bryostatin 1 | 3 |
| iGMDRD409 | Saracatinib | 2 |
| iGMDRD12 | Bicalutamide | 1 |
| iGMDRD889 | Compound 7d-cis | 4 |
| iGMDRD749 | ZINC6718453 | 1 |
| iGMDRD546 | BMS-754807 | 5 |
| iGMDRD476 | WH-4-023 | 1 |
| iGMDRD403 | BAY 61-3606 | 2 |
| iGMDRD748 | PHA-665752 | 2 |
| iGMDRD61 | Kinetin riboside | 6 |
| iGMDRD259 | EX-527 | 1 |
| iGMDRD470 | Trametinib | 6 |
| iGMDRD1032 | VNLG/124 | 1 |
| iGMDRD920 | HSP90 inhibitor | 2 |
| iGMDRD458 | GSK-319347A | 1 |
| iGMDRD493 | GSK269962A | 1 |
| iGMDRD468 | AZ628 | 1 |
| iGMDRD133 | Lapatinib | 1 |
| iGMDRD543 | GDC-0449 | 1 |
| iGMDRD23 | Gossypol | 4 |
| iGMDRD978 | Pembrolizumab | 1 |
| iGMDRD602 | Foretinib | 2 |
| iGMDRD382 | CEP-701 | 1 |
| iGMDRD607 | Ubistatin B | 7 |
| iGMDRD347 | Y-39983 | 2 |
| iGMDRD456 | Crizotinib | 2 |
| iGMDRD614 | Dabrafenib | 9 |
| iGMDRD232 | FTI-277 | 1 |
| iGMDRD784 | QL-X-138 | 1 |
| iGMDRD178 | MG-132 | 1 |
| iGMDRD374 | Zibotentan (ZD4054) | 1 |
| iGMDRD746 | CDK9 Inhibitor | 1 |
| iGMDRD558 | CAY10603 | 1 |
| iGMDRD278 | TTNPB | 4 |
| iGMDRD68 | Paclitaxel | 1 |
| iGMDRD504 | Obatoclax | 1 |
| iGMDRD1015 | THZ-2-102-1 | 1 |
| iGMDRD472 | PF-562271 | 1 |
| iGMDRD505 | Pevonedistat | 2 |
| iGMDRD353 | PD0325901 | 4 |
| iGMDRD136 | Nutlin-3 | 1 |
| iGMDRD554 | CHEMBL1434137 | 4 |
| iGMDRD387 | CHIR-99021 | 3 |
| iGMDRD54 | Phenformin | 1 |
| iGMDRD678 | Tubastatin A | 1 |
| iGMDRD239 | Dasatinib | 1 |
| iGMDRD328 | AR-42 | 1 |
| iGMDRD587 | CHEMBL585951 | 1 |
| iGMDRD632 | CP466722 | 2 |
| iGMDRD189 | CGP 60474 | 1 |
| iGMDRD608 | Refametinib | 6 |
| iGMDRD193 | Fqi1 | 2 |
| iGMDRD696 | NG25 | 2 |
| iGMDRD401 | Afatinib | 1 |
| iGMDRD673 | LSM-1215 | 1 |
| iGMDRD916 | Genentech Cpd 10 | 1 |
| iGMDRD491 | TAE-684 | 2 |
| iGMDRD700 | AUY922 | 1 |
| iGMDRD109 | Gefitinib | 1 |
| iGMDRD758 | JW-7-24-1 | 1 |
| iGMDRD759 | PFI-1 | 1 |
| iGMDRD318 | PAC-1 | 1 |
| iGMDRD388 | YM201636 | 2 |
| iGMDRD870 | BRD63610 | 2 |
| iGMDRD574 | Ruxolitinib | 1 |
| iGMDRD596 | Vemurafenib | 9 |
| iGMDRD312 | Pelitinib | 1 |
| iGMDRD332 | A-770041 | 2 |
| iGMDRD55 | Pyrazolanthrone | 1 |
| iGMDRD562 | Navitoclax | 1 |
| iGMDRD183 | CDK4/6 inhibitor | 6 |
| iGMDRD131 | Erlotinib | 2 |
| iGMDRD564 | GSK-650394 | 2 |
| iGMDRD330 | BRD4132 | 1 |
| iGMDRD370 | TPCA-1 | 2 |
| iGMDRD324 | CI-1040 | 3 |
| iGMDRD532 | Olaparib | 1 |
| iGMDRD594 | AZD-8055 | 1 |
| iGMDRD461 | VX-11e | 1 |
| iGMDRD376 | Tivozanib | 1 |
| iGMDRD541 | SNX-2112 (PF-04928473) | 1 |
| iGMDRD605 | AZD6482 | 1 |
| iGMDRD176 | Decitabine | 1 |
| iGMDRD705 | Nakiterpiosin | 2 |
| iGMDRD667 | BIX02189 | 1 |
| iGMDRD655 | SCHEMBL618594 | 1 |
| iGMDRD839 | BRAF inhibitor | 4 |
| iGMDRD442 | BMS-509744 | 1 |
| iGMDRD286 | Nsc 632839 | 2 |
| iGMDRD968 | Pan-RAF inhibitor | 2 |
| iGMDRD366 | PI-103 | 2 |
| iGMDRD263 | AACOCF3 | 1 |
| iGMDRD126 | Tipifarnib | 1 |
| iGMDRD151 | CHM-1 | 3 |
| iGMDRD571 | Cabozantinib | 1 |
| iGMDRD443 | Linifanib | 1 |
| iGMDRD937 | KIN001-236 | 1 |
| iGMDRD420 | Leucascandrolide A | 2 |
| iGMDRD427 | ABT737 | 7 |
| iGMDRD135 | Lenalidomide | 1 |
| iGMDRD781 | Sirolimus | 4 |
| iGMDRD394 | BX-795 | 1 |
| iGMDRD687 | I-BET151 | 1 |
| iGMDRD449 | RO4987655 | 1 |
| iGMDRD507 | GSK690693 | 1 |
| iGMDRD983 | PI3K pathway inhibitor | 2 |
| iGMDRD284 | Palbociclib | 2 |
| iGMDRD429 | Amuvatinib | 1 |
| iGMDRD117 | Docetaxel | 1 |
| iGMDRD44 | Temozolomide | 3 |
| iGMDRD593 | CX-5461 | 1 |
| iGMDRD52 | Rotenone | 1 |
| iGMDRD188 | Piperlongumine | 2 |
| iGMDRD399 | Selumetinib | 20 |
| iGMDRD506 | Fedratinib | 6 |
| iGMDRD190 | Nilotinib | 2 |
| iGMDRD41 | Imatinib | 1 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in NRAS
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.